Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation

Journal of Investigative Dermatology

Volumn 134, Issue 9, 2014, Pages 2390-2398

  Prickett, Todd D ^a   Zerlanko, Brad J ^a   Hill, Victoria K ^a   Gartner, Jared J ^a   Qutob, Nouar ^b   Jiang, Jiji ^a   Simaan, May ^c   Wunderlich, John ^d   Gutkind, J Silvio ^c   Rosenberg, Steven A ^d   Samuels, Yardena ^a,b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; GLUTAMATE RECEPTOR 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; SHORT HAIRPIN RNA; GRIN1 PROTEIN, HUMAN; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NERVE PROTEIN; SMALL INTERFERING RNA; IONOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL MUTANT; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; GENE LOSS; GENETIC ANALYSIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; WILD TYPE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR SUPPRESSOR GENE; HUMAN CELL;

CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; MELANOMA; MUTATION; NERVE TISSUE PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84906315021     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.190     Document Type: Article

References (31)

1. Berger MF, Hodis E, Heffernan TP, et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6
2. Carvill GL, Regan BM, Yendle SC, et al. (2013). GRIN2A mutations cause epilepsy-Aphasia spectrum disorders. Nat Genet 45:1073-6
3. Choo AM, Geddes-Klein DM, Hockenberry A, et al. (2012). NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult. Neurochem Int 60:506-16
4. Doronzo G, Russo I, Del Mese P, et al. (2010). Role of NMDA receptor in homocysteine-induced activation of mitogen-Activated protein kinase and phosphatidyl inositol 3-kinase pathways in cultured human vascular smooth muscle cells. Thromb Res 125:e23-32
5. Endele S, Rosenberger G, Geider K, et al. (2010). Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42:1021-6
6. Hahn CG, Wang HY, Cho DS, et al. (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12:824-8
7. Hodis E, Watson IR, Kryukov GV, et al. (2012). A landscape of driver mutations in melanoma. Cell 150:251-63
8. Kaderlik KR, Minchin RF, Mulder GJ, et al. (1994). Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-Amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. Carcinogenesis 15:1703-9
9. Kim MS, Chang X, Nagpal JK, et al. (2008). The N-methyl-D-Aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene 27:2045-54
10. Komuro H, Rakic P. (1993). Modulation of neuronal migration by NMDA receptors. Science 260:95-7
11. Lang UE, Puls I, Muller DJ, et al. (2007). Molecular mechanisms of schizophrenia. Cell Physiol Biochem 20:687-702
12. Lau A, Tymianski M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460:525-42
13. Lemke JR, Lal D, Reinthaler EM, et al. (2013). Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet 45:1067-72
14. Lesca G, Rudolf G, Bruneau N, et al. (2013). GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 45:1061-6
15. Maki BA, Cole R, Popescu GK. (2013). Two serine residues on GluN2A C-Terminal tails control NMDA receptor current decay times. Channels (Austin) 7:126-32
16. Monyer H, Sprengel R, Schoepfer R, et al. (1992). Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256:1217-21
17. Nacher J, McEwen BS. (2006). The role of N-methyl-D-Asparate receptors in neurogenesis. Hippocampus 16:267-70
18. Palavalli LH, Prickett TD, Wunderlich JR, et al. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518-20
19. Prickett TD, Agrawal NS, Wei X, et al. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32
20. Ru W, Peng Y, Zhong L, et al. (2012). A role of the mammalian target of rapamycin (mTOR) in glutamate-induced down-regulation of tuberous sclerosis complex proteins 2 (TSC2). J Mol Neurosci 47:340-5
21. Rzeski W, Turski L, Ikonomidou C. (2001). Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98:6372-7
22. Schlett K. (2006). Glutamate as a modulator of embryonic and adult neurogenesis. Curr Top Med Chem 6:949-60
23. Stark MS, Woods SL, GartsiDe MG, et al. (2011). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 44:165-9
24. Stepulak A, Luksch H, Gebhardt C, et al. (2009). Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435-45
25. Takano T, Lin JH, Arcuino G, et al. (2001). Glutamate release promotes growth of malignant gliomas. Nat Med 7:1010-5
26. Traynelis SF, Wollmuth LP, McBain CJ, et al. (2010). Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol Rev 62: 405-96
27. Wang JQ, Fibuch EE, Mao L. (2007). Regulation of mitogen-Activated protein kinases by glutamate receptors. J Neurochem 100:1-11
28. Wang XF, Zhou QM, Du J, et al. (2013). Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. Anticancer Agents Med Chem 13:923-31
29. Wei X, Walia V, Lin JC, et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6
30. Xiao L, Hu C, Feng C, et al. (2011). Switching of N-methyl-D-Aspartate (NMDA) receptor-favorite intracellular signal pathways from ERK1/2 protein to p38 mitogen-Activated protein kinase leads to developmental changes in NMDA neurotoxicity. J Biol Chem 286:20175-93
31. Ye ZC, Sontheimer H. (1999). Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59:4383-91.